| Prescription ID | TCMF7326 |
| Pinyin Name | Dao Chi San |
| Chinese Name | 导赤散 |
| English Name | Dao Chi Powder |
| Function Description | å£ç³œèˆŒç–®, å°ä¾¿èµ¤æ¶©, çƒæ·‹ä¸åˆ© |
| Indications | Heat stranguria disorder, Acute prostatitis, Chronic prostatitis, Salmonella pyelonephritis, Chronic pyelonephritis, Cystitis, Urethritis |
| Disease ICD-11 Category |
SA91 [Heat stranguria disorder (TM1), çƒæ·‹ (TM1)
]; GA91.Y [Other specified inflammatory and other diseases of prostate, 其他特指的å‰åˆ—腺炎性疾病 ]; GA91.0 [Chronic prostatitis, 慢性å‰åˆ—腺炎 ]; GC2Z [Diseases of the urinary system, unspecified, 泌尿系统疾病,未特指的 ]; GB55.Z [Chronic tubulo-interstitial nephritis, unspecified, 慢性肾å°ç®¡-间质肾炎,未特指的 ]; GC00 [Cystitis, 膀胱炎 ]; GC02.Y [Other specified urethritis and urethral syndrome, 其他特指的尿é“炎和尿é“综åˆå¾ ]; |
| Human Tissues Associated with Indication | Lung, Bladder |
| Reference | Taiwan Herbal Pharmacopeia 2nd Edition English Version |
| Reference Book/link | https://www.mohw.gov.tw/cp-3690-39025-2.html |
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH628 | Glycyrrhiza uralensis | ç”˜è‰ | TCMH628 | ITSAM892-14 |
| TCMH1531 | Akebia quinata | 木通 | TCMH1531 | ITSAJ4440-14 |
| TCMH1896 | Radix rehmanniae | 生地黄 | TCMH1896 | |
| TCMH2696 | Phyllostachys nigra | ç«¹å¶ | TCMH2696 | BBOBC006-15 |
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT45 | APP | Beta amyloid A4 protein | Unclassified | P05067 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1212 | Verticillium dahliae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1245 | Phytophthora cactorum |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1408 | Colletotrichum gloeosporioides |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1444 | Fusarium oxysporum |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1465 | Entamoeba histolytica |
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, APP, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 10.9358 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.91244 |
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.91244 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, AKR1B1, AKR1B10, APP, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.90261 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.5828 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, TYR | 6.85179 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7, CA9 | 6.73587 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, APP, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FUT7, GBA2, TYR, XDH | 6.62449 |
| [BP] GO:0008152 | metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, APP, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 6.58191 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, APP, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, HSD11B2, TYR | 5.91707 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, APP, BCL2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, TYR | 5.85272 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.67071 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.59788 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.94531 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, APP, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, TYR | 4.91764 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, APP, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, FUT7, GBA2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 4.89224 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.5942 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, AKR1B1, APP, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, FABP3, FABP4, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TNKS, TNKS2, XDH | 4.48769 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.45981 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2 | 4.45981 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, APP, BCL2, CYP19A1, CYP1A1, CYP1B1, GBA2, TYR | 4.15963 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 4.05276 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.95855 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, HSD11B1, HSD17B2, TYR | 3.77354 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, APP, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, HSD11B2 | 3.77354 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, APP, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, HSD11B2, HSD17B2, TYR | 3.74 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.36851 |
| [BP] GO:0016042 | lipid catabolic process | AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4, GBA2 | 3.32885 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.267 |
| [BP] GO:0032502 | developmental process | ACHE, AKR1B1, ALPL, APP, BCL2, CA2, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FABP4, FUT7, GBA2, HSD11B1, HSD17B2, TNKS2, TYR | 3.25406 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3 | 3.1829 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 3.06278 |
| [BP] GO:0010035 | response to inorganic substance | AKR1B1, APP, BCL2, CA2, CYP1A1, CYP1A2, CYP1B1, FABP4 | 2.91585 |
| [BP] GO:0048856 | anatomical structure development | ACHE, AKR1B1, ALPL, APP, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, GBA2, HSD11B1, HSD17B2, TYR | 2.8792 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.8554 |
| [BP] GO:0044238 | primary metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, APP, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 2.72022 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.69764 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.50026 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3 | 2.46537 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.43914 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.43914 |
| [BP] GO:0010647 | positive regulation of cell communication | AKR1B1, APP, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, PTPN1, TNKS, TNKS2, XDH | 2.43914 |
| [BP] GO:0023056 | positive regulation of signaling | AKR1B1, APP, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, PTPN1, TNKS, TNKS2, XDH | 2.42522 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.41383 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.36803 |
| [BP] GO:0071704 | organic substance metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, APP, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 2.35268 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2 | 2.35268 |
| [BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.3084 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.20504 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.20504 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.20504 |
| [BP] GO:0044242 | None | AKR1B10, CYP1B1, FABP3, FABP4, GBA2 | 2.19768 |
| [BP] GO:0035265 | organ growth | BCL2, CYP19A1, ESR1 | 2.11796 |
| [BP] GO:1901575 | None | ACHE, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, XDH | 2.04627 |
| [BP] GO:0009056 | catabolic process | ACHE, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, XDH | 2.03224 |
| [BP] GO:0043696 | None | CDK6, ESRRB | 2.0296 |
| [BP] GO:0043697 | None | CDK6, ESRRB | 2.0296 |
| [BP] GO:0010038 | response to metal ion | APP, BCL2, CA2, CYP1A1, CYP1A2, FABP4 | 2.0296 |
| [BP] GO:1901360 | None | ACHE, AKR1B1, AKR1B10, AOX1, APP, BCL2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 2.00021 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, AKR1B1, AKR1B10, AOX1, APP, BCL2, CA1, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FABP3, FABP4, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 2.09241 |
| [CC] GO:0044432 | endoplasmic reticulum part | APP, BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 2.06799 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.82225 |
| [CC] GO:0097386 | None | AKR1B1, APP | 1.11097 |
| [CC] GO:0000242 | None | TNKS, TNKS2 | 1.00642 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 10.9701 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, APP, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PTPN1, TNKS, TYR, XDH | 10.9358 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.39959 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 6.59792 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 6.40816 |
| [MF] GO:0003824 | catalytic activity | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PTPN1, TNKS, TNKS2, TYR, XDH | 6.19258 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.91707 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, APP, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD17B1, PTPN1, TNKS, TNKS2, TYR, XDH | 5.03965 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.78297 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, PTPN1, TNKS | 4.50174 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 4.27558 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, APP, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PTPN1, TNKS, TNKS2, TYR, XDH | 4.17677 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 4.10648 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.08203 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.92923 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.8715 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.77354 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, APP, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, PTPN1, TNKS, TNKS2, TYR, XDH | 3.7468 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.43147 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 3.24537 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 3.11868 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.08715 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 3.01088 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB | 2.96836 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB | 2.96836 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.8554 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.8554 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, XDH | 2.80935 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB | 2.69965 |
| [MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD11B2, HSD17B1 | 2.69267 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.37852 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.20504 |
| [MF] GO:0030284 | estrogen receptor activity | ESR1, ESR2 | 2.0296 |
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 | 13 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 11.127 |
| Metabolic pathways_Homo sapiens_hsa01100 | AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 6.0347 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 6.0347 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.734 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.7575 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.6238 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.5797 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, CDC25B | 1.8259 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.8617 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.9147 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.498 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 2.1048 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.8617 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.4053 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.4174 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.8965 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.4046 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | BCL2, F3 | 1.2441 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4 | 1.4174 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.321 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.184 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | ESR1, ESR2 | 1.2441 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.2757 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2 | 1.0256 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 1.0675 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 1.1107 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.991 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.8748 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2 | 0.6578 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, BCL2 | 0.6171 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.6726 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.7126 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.6726 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.6684 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.6688 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.6328 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.6801 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4 | 0.7126 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.6171 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6684 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.6171 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.6328 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1 | 0.6015 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.6171 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.6173 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6688 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.6688 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.6173 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.561 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.7469 |
| Serotonergic synapse_Homo sapiens_hsa04726 | APP | 0.5974 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.5959 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.5959 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6578 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5959 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.561 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.6457 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.561 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.561 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | BCL2 | 0.5959 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.561 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.5511 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.5129 |
| Alzheimer's disease_Homo sapiens_hsa05010 | APP | 0.5129 |
| Purine metabolism_Homo sapiens_hsa00230 | XDH | 0.5047 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.7319 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | ESR1 | 0.475 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.4045 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.475 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.7469 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | CDK6 | 0.475 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.5047 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4961 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.7469 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.791 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.7469 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.8807 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.8748 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.4014 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.8807 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.8894 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.8864 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 1.0185 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 1.0819 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.3216 |